rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Eton Pharmaceuticals, Inc.

ETON · Nasdaq

Health CarePharmaceuticalsLeading

ETON stood above a rising 150-day average in 40 of the last 52 weekly readings, including each of the last 36 weeks. It is 24.7% above that average now. Pharmaceuticals: 32% of its 74 stocks in an uptrend (−9 points in four weeks); Health Care: 28% (−9 points in four weeks).

SEC filings

Statistics

Rotation
Leading
Weeks in an uptrend
36 in a row
Industry in uptrend
32% -10 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$58.6M
Officials’ trades on record
0
Institutions holding
158 (+48)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 40 of 52 weeks.

21 Apr – 20 Oct
24%34%45%Apr 26Jun 26Jul 26Sep 26Oct 26

Pharmaceuticals: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$26.3M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months16
Buyers · sellers0 · 5
WhoDidSharesTraded
David KrempaChief Business Officersold4,166at $55.076 Oct 2026filed 6 Oct 2026
Paul V. MaierDirectorsold36,387at $58.6428 Aug 2026filed 28 Aug 2026
Paul V. MaierDirectorsold13,485at $60.2128 Aug 2026filed 28 Aug 2026
Paul V. MaierDirectorsold128at $61.7728 Aug 2026filed 28 Aug 2026
Paul V. MaierDirectorsold36,387at $58.6428 Aug 2026filed 31 Aug 2026
Paul V. MaierDirectorsold13,485at $60.2128 Aug 2026filed 31 Aug 2026
Paul V. MaierDirectorsold128at $61.7728 Aug 2026filed 31 Aug 2026
David KrempaChief Business Officersold25,000at $65.0724 Aug 2026filed 24 Aug 2026
Sean BrynjelsenPresident & CEOsold47,307at $60.1720 Aug 2026filed 20 Aug 2026
Sean BrynjelsenPresident & CEOsold36,373at $61.1120 Aug 2026filed 20 Aug 2026
Sean BrynjelsenPresident & CEOsold7,342at $62.1220 Aug 2026filed 20 Aug 2026
Sean BrynjelsenPresident & CEOsold8,978at $62.6519 Aug 2026filed 20 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders158+48 on the quarter
New · exited54 · 6
Reported value$712.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Opaleye Management Inc.unchanged · filed 14 Aug 20262,860,000$103.5M00.0%
EcoR1 Capital, LLCunchanged · filed 14 Aug 20262,171,938$78.6M00.0%
BlackRock, Inc.added · filed 7 Aug 20261,895,833$68.6M+178,547+10.4%
Nantahala Capital Management, LLCunchanged · filed 14 Aug 20261,175,951$42.6M00.0%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026976,570$35.4M-17,519−1.8%
MORGAN STANLEYadded · filed 13 Aug 2026767,972$27.8M+290,015+60.7%
STATE STREET CORPadded · filed 7 Aug 2026701,786$25.4M+171,571+32.4%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026652,303$23.6M+74,637+12.9%
OBERWEIS ASSET MANAGEMENT INCadded · filed 14 Aug 2026501,600$18.2M+62,300+14.2%
National Philanthropic Trustunchanged · filed 14 Aug 2026492,112$17.8M00.0%
31 Mar 2023 – 30 Jun 2026
3795153Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

David Krempa Company insiderChief Business Officer · last 6 Oct 20260 · 8
Paul Maier V Company insiderDirector · last 28 Aug 20261 · 2
Sean Brynjelsen Company insiderPresident & CEO · last 20 Aug 20267 · 6
Charles J. Casamento Company insiderDirector · last 31 Jul 20262 · 0
Ipek Erdogan-Trinkaus Company insiderChief Commercial Officer · last 31 Jul 20260 · 0
Jennifer McKie Adams Company insiderDirector · last 31 Jul 20260 · 1
Judith M. Matthews Company insiderChief Financial Officer · last 31 Jul 20260 · 0
Norbert G. Riedel Company insiderDirector · last 31 Jul 20261 · 0
Opaleye Management Inc. Company insider10% owner · last 14 Jul 20268 · 23
James R. Gruber Company insiderChief Financial Officer · last 14 Jan 20260 · 2
William Wilson Troutman Company insiderCFO and Secretary · last 7 Feb 20222 · 0
Harrow Health, Inc. Company insider10% owner · last 12 Apr 20210 · 1

Same industry

PCRX Pacira BioSciencesLeading+45%
CORT Corcept TherapeuticsLeading+38%
TTRX Turn TherapeuticsLeading+36%
RIGL Rigel PharmaceuticalsLeading+29%
AMRX Amneal PharmaceuticalsLeading+24%
ABBV AbbVieLeading+22%
TEVA Teva Pharmaceutical IndustriesLeading+18%
LLY Eli Lilly andLeading+17%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202553.5%
Operating profit marginFY 2025 · to 31 Dec 2025-1.1%
Free cash flow marginFY 2025 · to 31 Dec 202512.7%
Return on capital employedFY 2025 · to 31 Dec 2025-1.6%
Debt to equityFY 2025 · to 31 Dec 20251.17×
Interest coverFY 2025 · to 31 Dec 2025-0.18×
Research spendFY 2025 · to 31 Dec 20259.7%
Share count trendFY 2025 · to 17 Mar 20260.9%
Cash and equivalentsFY 2025 · to 31 Dec 2025$25.9M
Free cash flowFY 2025 · to 31 Dec 2025$10.2M

Analyst forecasts

No analyst forecasts yet.